deltatrials
Completed PHASE2 NCT00003731

Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors

First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Brain and Central Nervous System Tumors
Interventions temozolomide
Updated 5 times since 2017 Last updated: Sep 20, 2012 Started: Dec 31, 1998 Primary completion: Jan 31, 2001

Listed as NCT00003731, this PHASE2 trial focuses on Brain and Central Nervous System Tumors and remains completed. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 5 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Dec 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • European Organisation for Research and Treatment of Cancer - EORTC
Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland, Bamberg, Germany, Basel, Switzerland, Berlin, Germany, Bern, Switzerland, Bratislava, Slovakia, Brussels, Belgium, Edinburgh, United Kingdom, Lausanne, Switzerland, Leuven, Belgium and 12 more location s